Published in Gut on December 09, 2011
To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia | NCT00761358
Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther (2012) 1.45
Functional dyspepsia--symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol (2013) 1.42
Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol (2015) 1.08
Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol (2013) 1.03
DA-9701: A New Multi-Acting Drug for the Treatment of Functional Dyspepsia. Biomol Ther (Seoul) (2013) 1.00
Why dyspepsia can occur without organic disease: pathogenesis and management of functional dyspepsia. J Gastroenterol (2012) 0.99
The stomach in health and disease. Gut (2015) 0.95
Functional dyspepsia: new insights into pathogenesis and therapy. Korean J Intern Med (2016) 0.92
Impact of sleep disorders, quality of life and gastric emptying in distinct subtypes of functional dyspepsia in Japan. J Neurogastroenterol Motil (2013) 0.89
Investigating functional dyspepsia in Asia. J Neurogastroenterol Motil (2012) 0.89
Visceral hypersensitivity and electromechanical dysfunction as therapeutic targets in pediatric functional dyspepsia. World J Gastrointest Pharmacol Ther (2014) 0.86
Overlap of functional dyspepsia and GERD--diagnostic and treatment implications. Nat Rev Gastroenterol Hepatol (2013) 0.84
Disorder of autonomic nervous system and its vulnerability to external stimulation in functional dyspepsia. J Clin Biochem Nutr (2016) 0.83
Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. J Clin Invest (2013) 0.83
Overlap between postprandial distress and epigastric pain syndromes in functional dyspepsia: its implications for research and clinical practice (am j gastroenterol 2013;108:767-774). J Neurogastroenterol Motil (2013) 0.82
Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis. ScientificWorldJournal (2014) 0.82
Clinical application of kampo medicine (rikkunshito) for common and/or intractable symptoms of the gastrointestinal tract. Front Pharmacol (2015) 0.80
Profile of acotiamide in the treatment of functional dyspepsia. Clin Exp Gastroenterol (2016) 0.78
Effect of DA-9701 on Gastric Motor Function Assessed by Magnetic Resonance Imaging in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial. PLoS One (2015) 0.77
Current management of functional dyspepsia: impact of Rome III subdivision. Ann Gastroenterol (2012) 0.76
A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia. J Gastroenterol (2016) 0.75
Effects of acotiamide on esophageal motor function and gastroesophageal reflux in healthy volunteers. BMC Gastroenterol (2015) 0.75
New hope for functional dyspepsia? Gut (2012) 0.75
Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. Biomed Rep (2016) 0.75
Analysis on Awareness of Functional Dyspepsia and Rome Criteria Among Japanese Internists by the Self-administered Questionnaires. J Neurogastroenterol Motil (2013) 0.75
Functional Dyspepsia: Advances in Diagnosis and Therapy. Gut Liver (2017) 0.75
Dyspepsia: Acotiamide can relieve symptoms of functional dyspepsia. Nat Rev Gastroenterol Hepatol (2012) 0.75
Editorial: Functional Dyspepsia Treatment: Trials and Tribulations of Targeted Strategies. Am J Gastroenterol (2017) 0.75
The Ameliorating Effect of Lactobacillus gasseri OLL2716 on Functional Dyspepsia in Helicobacter pylori-Uninfected Individuals: A Randomized Controlled Study. Digestion (2017) 0.75
The Implication of Gastric Dysmotility in the Pathophysiology of Functional Dyspepsia. J Neurogastroenterol Motil (2017) 0.75
The Application of the Rome IV Criteria to Functional Esophagogastroduodenal Disorders in Asia. J Neurogastroenterol Motil (2017) 0.75
A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia. Digestion (2017) 0.75
Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials (1989) 15.99
Functional gastroduodenal disorders. Gastroenterology (2006) 8.51
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med (1998) 4.66
A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med (2006) 2.94
Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol (1996) 2.73
American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology (2005) 2.39
Guidelines for the management of dyspepsia. Am J Gastroenterol (2005) 2.39
A comparison of Likert and visual analogue scales for measuring change in function. J Chronic Dis (1987) 2.32
Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut (2007) 2.11
A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol (2005) 1.94
Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther (2003) 1.82
Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl (1999) 1.69
Functional dyspepsia impacts absenteeism and direct and indirect costs. Clin Gastroenterol Hepatol (2010) 1.65
Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study. Aliment Pharmacol Ther (2005) 1.62
5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil (2008) 1.59
Functional heartburn: the stimulus, the pain, and the brain. Gut (2002) 1.51
Influence of experimentally induced anxiety on gastric sensorimotor function in humans. Gastroenterology (2005) 1.46
Validity of a new quality of life scale for functional dyspepsia: a United States multicenter trial of the Nepean Dyspepsia Index. Am J Gastroenterol (1999) 1.44
The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval. Clin Pharmacol Ther (2008) 1.41
Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. Am J Gastroenterol (2010) 1.33
Prevalence of functional dyspepsia in an outpatient clinic with primary care physicians in Japan. J Gastroenterol (2009) 1.32
Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form. Aliment Pharmacol Ther (2001) 1.25
Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther (1999) 1.20
Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol (2001) 1.16
Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil (2010) 1.13
A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil (2009) 1.12
Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol (2008) 1.07
Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial. Am J Gastroenterol (2006) 1.04
Minimum clinically important difference for the Nepean Dyspepsia Index, a validated quality of life scale for functional dyspepsia. Am J Gastroenterol (2009) 1.03
Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther (2002) 1.00
Review article: endpoints used in functional dyspepsia drug therapy trials. Aliment Pharmacol Ther (2011) 1.00
Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil (2008) 0.99
Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia. Expert Opin Investig Drugs (2011) 0.96
Prevalence of functional dyspepsia and its relationship with Helicobacter pylori infection in a Japanese population. J Gastroenterol Hepatol (2001) 0.96
Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J Pharmacol Exp Ther (2000) 0.93
Influence of acute tryptophan depletion on gastric sensorimotor function in humans. Am J Physiol Gastrointest Liver Physiol (2010) 0.89
Functional Dyspepsia: A New Rome III Paradigm. Curr Treat Options Gastroenterol (2007) 0.89
Z-338, a newly synthetized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission. J Smooth Muscle Res (2000) 0.86
The spectra of functional gastrointestinal disorders (FGID) in a Japanese hospital outpatient department according to the ROME II Integrative Questionnaire. J Gastroenterol Hepatol (2008) 0.81
Tegaserod: withdrawal from the world market. A treatment for constipation with cardiovascular adverse effects. Prescrire Int (2008) 0.80
IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol (2005) 18.32
5'-Triphosphate RNA is the ligand for RIG-I. Science (2006) 15.78
A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol (2005) 7.94
Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. N Engl J Med (2011) 6.76
Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity (2009) 5.70
Essential role of IPS-1 in innate immune responses against RNA viruses. J Exp Med (2006) 5.01
Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nat Cell Biol (2009) 4.78
The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology (2007) 4.58
Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat Immunol (2006) 4.15
Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol (2009) 3.58
Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol (2008) 3.55
Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature (2009) 3.50
Outcomes of treatment for achalasia depend on manometric subtype. Gastroenterology (2012) 3.35
The yield of upper gastrointestinal endoscopy in patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am J Gastroenterol (2004) 3.25
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med (2008) 3.13
Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol (2013) 2.98
Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J Exp Med (2005) 2.90
LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. Proc Natl Acad Sci U S A (2010) 2.90
Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity (2007) 2.78
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol (2005) 2.68
Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther (2008) 2.50
Activation of MDA5 requires higher-order RNA structures generated during virus infection. J Virol (2009) 2.37
Feasibility of combined use of intravascular ultrasound radiofrequency data analysis and optical coherence tomography for detecting thin-cap fibroatheroma. Eur Heart J (2008) 2.36
Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography. JACC Cardiovasc Interv (2009) 2.29
Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol (2008) 2.28
Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut (2013) 2.26
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med (2007) 2.23
The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol (2013) 2.21
Long-term outcome of pneumatic dilation in the treatment of achalasia. Clin Gastroenterol Hepatol (2009) 2.10
Pro: Impedance testing is useful in the management of GERD. Am J Gastroenterol (2009) 2.09
Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med (2014) 2.05
Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol (2003) 2.04
Characteristics and clinical relevance of proximal esophageal pH monitoring. Am J Gastroenterol (2004) 2.01
Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells and induces a cytotoxic T-cell response via MyD88. J Virol (2007) 1.99
Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res (2004) 1.88
Proteins of nucleotide and base excision repair pathways interact in mitochondria to protect from loss of subcutaneous fat, a hallmark of aging. J Exp Med (2010) 1.86
Reproducibility and agreement of pharyngeal automated impedance manometry with videofluoroscopy. Clin Gastroenterol Hepatol (2011) 1.84
A novel method for the nonradiological assessment of ineffective swallowing. Am J Gastroenterol (2011) 1.81
The ability of optical coherence tomography to monitor percutaneous coronary intervention: detailed comparison with intravascular ultrasound. J Invasive Cardiol (2010) 1.79
Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci (2003) 1.75
TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat Immunol (2009) 1.72
Bitter taste receptors and α-gustducin regulate the secretion of ghrelin with functional effects on food intake and gastric emptying. Proc Natl Acad Sci U S A (2011) 1.69
Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol (2012) 1.66
Asian consensus on irritable bowel syndrome. J Gastroenterol Hepatol (2010) 1.64
Nerve activity recordings in routine human intestinal biopsies. Gut (2012) 1.59
Regional brain activation during proximal stomach distention in humans: A positron emission tomography study. Gastroenterology (2005) 1.58
Herpes simplex virus infection is sensed by both Toll-like receptors and retinoic acid-inducible gene- like receptors, which synergize to induce type I interferon production. J Gen Virol (2009) 1.56
Gastric fullness, physical activity, and proximal extent of gastroesophageal reflux. Am J Gastroenterol (2005) 1.56
Protein kinase R contributes to immunity against specific viruses by regulating interferon mRNA integrity. Cell Host Microbe (2010) 1.56
Decompression of idiopathic lumbar epidural lipomatosis: diagnostic magnetic resonance imaging evaluation and review of the literature. J Neurosurg Spine (2006) 1.54
Botulinum toxin reduces Dysphagia in patients with nonachalasia primary esophageal motility disorders. Clin Gastroenterol Hepatol (2013) 1.50
Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol (2004) 1.50
Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology (2007) 1.48
Influence of experimentally induced anxiety on gastric sensorimotor function in humans. Gastroenterology (2005) 1.46
Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol (2005) 1.44
Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am J Gastroenterol (2012) 1.41
Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis. Intern Med (2011) 1.41
Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problems have more impaired psychological distress. Dig Dis Sci (2004) 1.39
A method to objectively assess swallow function in adults with suspected aspiration. Gastroenterology (2011) 1.35
Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling. J Exp Med (2007) 1.34
Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology (2006) 1.33
Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique. Gut (2011) 1.32
Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. Gut (2009) 1.31
MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol Ther (2010) 1.30
Cutting edge: Role of TANK-binding kinase 1 and inducible IkappaB kinase in IFN responses against viruses in innate immune cells. J Immunol (2006) 1.30
Central nervous system involvement in functional gastrointestinal disorders. Best Pract Res Clin Gastroenterol (2004) 1.29
Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways. J Immunol (2009) 1.29
Relationship between anxiety and gastric sensorimotor function in functional dyspepsia. Psychosom Med (2007) 1.28
Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL. Qual Life Res (2004) 1.26
Specific brain processing of facial expressions in people with alexithymia: an H2 15O-PET study. Brain (2003) 1.26
Factors related to long-term outcome after decompressive surgery for ossification of the ligamentum flavum of the thoracic spine. J Neurosurg (2003) 1.25
Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis. Hum Mol Genet (2010) 1.22
Visceral hypersensitivity in irritable bowel syndrome. J Gastroenterol Hepatol (2011) 1.22
A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol (2008) 1.22
Dyspepsia: organic versus functional. J Clin Gastroenterol (2012) 1.20
The viral RNA recognition sensor RIG-I is degraded during encephalomyocarditis virus (EMCV) infection. Virology (2009) 1.19
Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series. J Bone Miner Metab (2012) 1.18
Heterogeneity of symptom pattern, psychosocial factors, and pathophysiological mechanisms in severe functional dyspepsia. Gastroenterology (2003) 1.17
Clinical features of cauda equina tumors requiring surgical treatment. Tohoku J Exp Med (2006) 1.17
A double-blind sham-controlled study of the effect of radiofrequency energy on symptoms and distensibility of the gastro-esophageal junction in GERD. Am J Gastroenterol (2011) 1.17
A novel insertion pathway of mitochondrial outer membrane proteins with multiple transmembrane segments. J Cell Biol (2007) 1.16
Food: the forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am (2011) 1.15
Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). Biopsychosoc Med (2007) 1.15
Disorders of gastrointestinal motility: towards a new classification. J Gastroenterol Hepatol (2002) 1.14
Colonic transit time and IBS symptoms: what's the link? Am J Gastroenterol (2012) 1.14
Encephalomyocarditis virus disrupts stress granules, the critical platform for triggering antiviral innate immune responses. J Virol (2013) 1.13
Giant cell tumor of fifth lumbar vertebrae: two case reports and review of the literature. Spine J (2006) 1.12
Influence of duodenal acidification on the sensorimotor function of the proximal stomach in humans. Am J Physiol Gastrointest Liver Physiol (2003) 1.12
Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J Nucl Med (2012) 1.11
Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index. J Gastroenterol (2006) 1.11
Critical role of stress in increased oesophageal mucosa permeability and dilated intercellular spaces. Gut (2007) 1.11
Identification of TIFA as an adapter protein that links tumor necrosis factor receptor-associated factor 6 (TRAF6) to interleukin-1 (IL-1) receptor-associated kinase-1 (IRAK-1) in IL-1 receptor signaling. J Biol Chem (2003) 1.11
Identification of a novel protein MICS1 that is involved in maintenance of mitochondrial morphology and apoptotic release of cytochrome c. Mol Biol Cell (2008) 1.10
Relationships between falls, spinal curvature, spinal mobility and back extensor strength in elderly people. J Bone Miner Metab (2009) 1.10
Inferior vena cava occluder for remote access perfusion in robotic cardiac surgery. Minim Invasive Ther Allied Technol (2010) 1.10
Asian consensus report on functional dyspepsia. J Neurogastroenterol Motil (2012) 1.09
Antibiotic therapy for the irritable bowel syndrome. N Engl J Med (2011) 1.09